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Background: Pyloric gland adenoma consists of closely packed pyloric-type glands lined by mucus-secreting cells.
To date, approximately 230 cases have been reported, mostly of gastric localization with a tumour size up to 3.5 cm
and a mean age of occurrence around 70 years. Adenocarcinoma develops in about 40% of cases and may be
difficult to detect due to relatively mild nuclear atypia.
Case presentation: We present the first case of a pyloric gland adenoma of the cystic duct in a 62-year-old male
patient and demonstrate the clinicopathologic characteristics, including radiographic, molecular, and cytogenetic
findings. The 2 cm-tumour developed in the cystic duct and protruded into the hepatic and common bile duct. On
microscopic examination, it displayed closely packed pyloric-type glands, and focal architectural distortion with mild
nuclear atypia. Immunohistochemically, it expressed MUC1, MUC5AC, MUC6 and p53, but not MUC2 and CD10. The
Ki67-proliferation index was 25%. Furthermore, high-grade intraepithelial neoplasia was observed in the surrounding
bile duct. We detected chromosomal gains at 7p, 7q11q21, 15q, 16p, 20, losses at 6p23pter, 6q, 18, and
amplifications at 1q and 6p21p22 in the pyloric gland adenoma by comparative genomic hybridization. A KRAS
codon 12 mutation (c.35G>T; p.G12V) was detected in the pyloric gland adenoma and in the adjacent dysplasia by
sequencing analysis. The diagnosis of pyloric gland adenoma was established with transition into well-differentiated
adenocarcinoma and high-grade biliary intraepithelial neoplasia.
Conclusion: Pyloric gland adenoma evolving in the cystic duct is a rare differential diagnosis of obstructive bile
duct tumours. Other premalignant bile duct lesions may be associated. Due to the risk of developing
adenocarcinoma, surgical resection should be performed.
Keywords: Pyloric gland adenoma, Adenocarcinoma, Cystic duct, Comparative genomic hybridization (CGH),
KRAS mutationBackground
Pyloric gland adenoma was first described in 1976 by
Kurt Elster. At that time, a neoplasm was not recog-
nized, but since 1990 pyloric gland adenoma has been
categorized as a distinct neoplastic entity in the WHO
classification of gastric tumours [1-3]. In the approxi-
mately 230 previously reported cases, the lesion was
mostly localized in the stomach (69%), followed by* Correspondence: schaeferinga@web.de
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reproduction in any medium, provided the orgallbladder (14%), duodenum (12%), esophagus, gastroe-
sophageal junction, bile duct, pancreatic duct, and rec-
tum (together <5%) [2-15]. In the stomach, the pyloric
gland adenoma accounts for <3% of gastric polyps [3].
Extra-gastric cases are even rarer and their incidence is
not known [3]. However, pyloric gland adenoma is
reported to be the most common type of benign epithe-
lial neoplasm of the gallbladder, although it rarely occurs
in the extrahepatic bile ducts [16]. The lesion occurs in
patients with a mean age of approximately 70 years, with
a reported mean tumour size of 0.6-3.5 cm, and a slight
female predominance [2-15]. It harbors the risk ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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up to 47% of cases of all locations [3]. The diagnosis of
pyloric gland adenoma can be established according to
the histological criteria proposed by Watanabe et al.:
closely packed pyloric-type glands, lined by cuboidal or
columnar mucus-secreting cells with round or oval, rela-
tively small, hyperchromatic nuclei with a parabasal loca-
tion; so-called lateral expansion or fusion of neighboring
foveolae indicate adenocarcinoma [3].
Three cases of pyloric gland adenoma of the common
bile duct have up to now been reported [7]. Here, we
present the first reported case of pyloric gland adenoma
evolving in the cystic duct, with transition into well-
differentiated adenocarcinoma, and associated high-grade
intraepithelial neoplasia of the adjacent bile duct. The
clinico-pathologic characteristics, including radiologic as
well as molecular and cytogenetic findings, will be demon-
strated with a review of the literature.
Case presentation
A 62-year-old male patient was admitted with a three-
week history of colic-like pain in the upper abdomen
and jaundice. He had a metabolic syndrome (body mass
index 45 kg/m2) including a fatty liver disease with be-
ginning fibrosis, and a history of smoking (25 pack
years). Abdominal computed tomography (CT) revealed
an approximately 3 × 2 cm polypoid mass lesion appar-
ently located in the common bile duct and along the
bifurcation into the cystic duct with consecutive dila-
tion of the central intra- and extrahepatic bile ducts
(Figure 1A, B), gallbladder hydrops and cholecystolithia-
sis. Laboratory tests detected an increase in total biliru-
bin (1.4 mg/dL; normal ≤1.2 mg/dL), aspartate amino
transferase (76 U/L; normal ≤35 U/L), alanine aminoFigure 1 Radiographic findings of the pyloric gland adenoma of the c
dilated intrahepatic bile ducts (A, arrow), and a polypoid tumour in the com
retrograde cholangiopancreatography confirmed the polypoid mass lesion
intrahepatic bile ducts. Endosonography verified the polypoid intraluminal
the portal vein.transferase (79 U/L; normal ≤45 U/L), and γ-glutamyl
transferase (223 U/L; normal ≤55 U/L). Levels of alpha-
fetoprotein (AFP) and carbohydrate antigen 19–9 (CA19-9)
were within normal range (AFP 3 μg/L; normal <7 μg/L,
and CA19-9 31 kU/L; normal <37 kU/L). As abdominal
ultrasound showed a dilated common hepatic duct of up to
2 cm, endoscopic retrograde cholangiopancreatography
(ERCP) was performed (Figure 1C). It revealed a mass
in the common hepatic duct and hematobilia. Via
passage with a blocked balloon, material was obtained
for histoxpathology. A stent was inserted into the bile
duct, producing immediate bile drainage. After that
intervention, the jaundice steadily declined and the chole-
static parameters normalized. The initial pathological
diagnosis of the obtained tissue was a tubulo-villous
adenoma of the bile duct.
After a four-week interval for weight reduction, ERCP
was re-performed and the stent was removed. Fluoro-
scopic guidance with contrast application revealed the
tumour in the middle part of the common bile duct. After
obtaining biopsies from the tumour, a stent was inserted
again for drainage until the operation. Endosonography
located the tumour in the common bile duct (Figure 1D)
and the cystic duct, protruding into the infundibulum of
the gallbladder. A suspect lymph node was detected
between bile duct and cystic duct.
Histopathological examination revealed tubulo-papillary
neoplastic proliferations and closely packed glandular struc-
tures with eosinophilic cytoplasm, round to oval nuclei and
inconspicuous nucleoli. At the surface, small papillary pro-
liferations were observed. Focally, marked architectural
distortion with nuclear atypia, hyperchromatic nuclei with
prominent nucleoli, and a back-to-back formation of
stellar glands were present. Squamous morules were notystic duct. Abdominal computed tomography revealed markedly
mon hepatic duct just below the bifurcation (B, arrow). Endoscopic
(C, arrow) and demonstrated consecutive dilation of the central
tumour of 2.1 x 1.1 cm in the common hepatic duct (D, arrow) next to
Figure 2 Gross findings of the resected pyloric gland adenoma. The resected specimen comprised the common bile duct (star), the bifurcation
into common hepatic duct (arrow) and cystic duct with attached gallbladder (A). Cross sections revealed an intraluminal tumour of 2.5 cm length
and 2 cm in diameter developing in the cystic duct (B), and protruding into the common bile duct and common hepatic duct (C, arrow).
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with possible transition into well-differentiated adeno-
carcinoma was established and confirmed by reference
pathology.
In the meantime the patient developed a thrombosis
of the right cephalic vein after catheter infection and a
non-ST-elevation myocardial infarction, which were trea-
ted non-interventionally with antibiotics and heparin for
prolongation of the prothrombin time. Two weeks
later, resection of the extrahepatic bile ducts including
gallbladder with biliodigestive anastomosis was performed.
The resected specimen of the common bile duct, cystic
duct with attached gallbladder, and common hepatic duct
presented a 2.5 × 2 cm tumour with a gray-brown cut sur-
face, developing in the cystic duct, and protruding
through the bifurcation into both the common bile duct
and common hepatic duct, with partial obstruction of the
lumen (Figure 2). The surrounding cystic duct showed
epithelial cell proliferations in the mucosa with moderate
and focal high-grade cellular atypia, outstretching into
small branching bile duct (Figure 3). Immunohistochem-
ical staining with MUC1 (clone MRQ-17, 1:300, Cell
marque/Medac, Wedel, Germany), MUC2 (clone MRQ-18,
1:100, Cell marque/Medac), MUC5AC (clone MRQ-19,
1:300, Cell marque/Medac), MUC6 (clone MRQ-20, 1:300,
Cell marque/Medac), vascular endothelial growth factorFigure 3 Microscopic findings of the pyloric gland adenoma and adja
adenoma arose in the cystic duct (right) and displayed a papillary, intralum
(A, H&E, x40). Closely packed pyloric type glands were lined by cuboidal to
distortion (C, x100) and high-grade dysplasia with nuclear atypia, indicating
high-grade intraepithelial neoplasia (BilIN-3) of the cystic duct was detected
neoplasm (IPN) with direct transition into the pyloric gland adenoma (F, x2receptor (VEGF; clone SP28, prediluted, Abcam, Cambridge,
MA, USA), CD10 (clone 56C6, 1:25, Zytomed Systems,
Berlin, Germany), CDX2 (clone EPR2764Y, 1:100, Cell
Marque, Rocklin, CA, USA), p53 (clone DO-7, 1:50, Dako,
Glostrup, Denmark), p21 (clone DCS-60.2, 1:100, Thermo
Scientific, Fremont, CA, USA), p16 (clone JC8, 1:100,
Santa Cruz Biotechnology, Heidelberg, Germany), and
Ki67 (clone K-2, 1:200 Zytomed Systems) was performed.
The pyloric gland adenoma showed focal positive staining
for MUC1, and negative staining for MUC2, as well as
superficial staining for MUC5AC, and positive expression
of MUC6 and VEGF (Figure 4). CD10 and CDX2 were
not expressed. Nuclear expression of p53, focal p16, and
p21 was observed. Proliferative activity was assessed by
Ki67 and estimated at 25%. The high-grade intraepithelial
neoplasia of the bile duct, in contrast, did not express
MUC1, MUC2, and MUC5AC, but MUC6 and VEGF.
Staining with CD10 and CDX2, p53, and p16 was nega-
tive, whereas p21 was only focally expressed. Prolifera-
tive activity was assessed by Ki67, and estimated at
10%. The diagnosis of a pyloric gland adenoma with
focal high-grade intraepithelial neoplasia and transi-
tion into well-differentiated gastric-type adenocarcin-
oma associated with BilIN-3 of the cystic duct
resembling gastric-type intraductal papillary neoplasm
in areas with low-grade intraepithelial neoplasia wascent bile duct lesions. On microscopic view, the pyloric gland
inal growth pattern with protrusion into the common bile duct (left)
columnar mucus-secreting cells (B, x100) with focal architectural
transition into well-differentiated adenocarcinoma (D, x200). Focal
(E, x200), focally resembling gastric-type intraductal papillary
00).
Figure 4 Immunohistochemical findings of the pyloric gland adenoma and adjacent bile duct lesions. The pyloric gland adenoma (A, HE)
immunohistochemically expressed focal MUC1 (B), but no MUC2 (C). MUC5AC (D) was positive predominantly in the superficial luminal cell layers,
whereas MUC6 (E) was expressed throughout. The tumour cell also expressed vascular endothelial growth factor receptor (VEGF) (F), but no CD10 (G)
and CDX2 (H). Nuclear p53 (I) was positive, p16 (J) was focally observed, and p21 (K) was positive. Ki67 (L) was observed in approximately 25% (x100).
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was finally staged at pT1, pNX, pMX, G1, L0, V0, R0.
Metastases had been excluded by CT scan.
CGH analysis was performed from the pyloric gland ad-
enoma as described previously [17] and revealed chro-
mosomal gains at 7p, 7q11q21, 15q, 16p, 20, losses at
6p23pter, 6q, 18, and amplifications at 1q and 6p21p22 in
the pyloric gland adenoma (Figure 5). Sequencing analysis
of KRAS exon 1 and 2 showed a point mutation at exon 1,
codon 12 (c.35G>T; p.G12V) and wildtype sequence at
exon 2 in the pyloric gland adenoma and the same muta-
tion in the adjacent BilIN-3. The patient recovered well
and was discharged 12 days after surgery. He presently
shows no signs of tumour relapse 12 months after
tumour resection.
The clinico-pathologic findings of previously reported
cases of pyloric gland adenoma [2-15] as well as the present
case are summarized in Table 1. The developmental etiologyof pyloric gland adenoma is still unclear, particularly when
observed in localizations other than gastric. However, the se-
quence of metaplasia-dysplasia and carcinoma is well
accepted as a histogenetic pathway of the gallbladder and
bile duct carcinogenesis [16,18]. For the development of pyl-
oric gland adenoma/adenocarcinoma, it is believed that the
first step may be initiated by the presence of gastric metapla-
sia or gastric heterotopias [6,7]. An association of pyloric
gland adenomas with heterotopic gastric mucosa or gas-
tric metaplasia in the gallbladder [14], pancreas [4], duo-
denum [15], and rectum [6] has previously been reported.
Above the designation as hyperplasia or hamartoma, some
authors suggest an unstable and precancerous nature by
proposing a “pyloric gland adenoma-adenocarcinoma se-
quence” by CGH analyses, and underline its high potential
for invasive malignancy [3,18]. Immunohistochemically, as
in the present case, the tumour typically expresses MUC6
and variably MUC5AC [2,3,6,8,9,11,12,14,15]. MUC2 and
Figure 5 Results of comparative genomic hybridization (CGH). CGH of the pyloric gland adenoma revealed ish cgh amp(1)(q),amp(6)
(p21p22),dim(6)(p23pter),dim(6)(q),enh(7)(p),enh(7)(q11q21),enh(15)(q),enh(16)(p),dim(18),enh(20) as indicated by green (gains) and red (losses)
bars. The number of chromosomes included in the CGH analysis is indicated at the bottom of each individual profile.
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from gastric to intestinal differentiation [2,3,8,12]. Add-
itionally, Ki67 expression and p53 mutations can be used
to detect malignant transformation [3]. The presence of
adenocarcinoma may be difficult to recognize since the
cytology of adenocarcinoma developing in pyloric gland
adenoma is known to show rather mild abnormalities
without the classical signs of intraepithelial neoplasia/dys-
plasia [3]. However, transition from round or oval nuclei
to elongated or pleomorphic nuclei with loss of polarity in
conjunction with so-called lateral expansion or branching
of glands indicates the presence of adenocarcinoma, as
found focally also in the present case (Figure 3) [3]. In
another study describing 3 pyloric gland adenocarcinomas
of the extrahepatic bile ducts the authors observed pyloric
gland metaplasia adjacent to the adenocarcinoma in 2 of 3
cases and suggested them as probable precursor lesion
[16]. These tumours did not arise from pyloric gland ad-
enomas, but displayed a similar immunophenotype with
positive expression of MUC5AC and MUC6 and negativity
for MUC2 and CDX2 [16]. Squamous morules (or spindle
cell metaplasias) are reported to occur in 23% of cases [9],
but were not observed in the present case.
Histopathological differential diagnoses of polypous
intraductal bile duct lesions include adenomas of the
gallbladder and extrahepatic bile ducts. They can be
divided into a tubular, papillary, and tubulopapillary type
based on their growth pattern, and cytologically into a
pyloric-gland, intestinal, foveolar, and biliary type [1].
IPN of gastric, pancreatobiliary, intestinal or oncocytic
phenotype, and mucinous cystic neoplasms should also
be considered [1]. Furthermore, concomitant intraductalpapillary mucinous neoplasms (IPMN) [5,13] have been
observed in cases of pancreatic pyloric gland adenomas.
In the pancreas, gastric-type IPMN are usually located
as small cystic lesions in branching ducts, harboring
only mild/low-grade atypia and immunohistochemically
expressing MUC5AC, but not MUC1, MUC2 or CDX2.
They are associated with a rather favorable clinical prog-
nosis compared to the other subtypes of IPMN [19];
adenocarcinoma occurs in 10-15% [19]. Invasive adeno-
carcinoma may also develop in IPN of the bile duct [1].
BilIN of the gallbladder and extrahepatic bile ducts are
associated with lithiasis in up to 3%, familial adenomatous
polyposis coli, sclerosing cholangitis, and pancreatobiliary
reflux [1]. Additionally, BilIN-3 usually arises in a associ-
ation with pyloric and intestinal metaplasia, as observed in
the present case, with an abrupt transition between normal
and atypical columnar cells [1]. As reported, BilIN
immunohistochemically also expresses p53 [1].
KRAS codon 12 mutations have been previously
reported in two cases of pyloric gland adenoma of the
main pancreatic duct, and probably support the neo-
plastic nature of this tumour [4,5]. KRAS (13-100%)
and TP53 (50%) mutations have been described for
IPMN of the pancreas before [19]. Also in the present
case, the pyloric gland adenoma and the BilIN-3 har-
bored a KRAS codon 12 mutation, indicating a pos-
sible metaplasia-dysplasia-carcinoma sequence with a
common tumourigenesis.
Previous CGH results of a pyloric gland adenoma of
the esophagus revealed chromosomal aberrations which
overlapped with findings in Barrett’s dysplasia and
adenocarcinoma as well as gastric cardia adenocarcinoma
Table 1 The clinico-pathologic characteristics of previously reported cases of pyloric gland adenoma [2-15] and the case reported here
Author (year) Number of
cases
Age/Sex Site Associated lesion Malignancy
developing
in PGA
Size (cm) Immunoreactivity Genetics
Kushima (1996) 1 61/F Gallbladder Gastric metaplasia – 1.5 MUC6 (= M2) n.k.
Bakotic (1999) 1 69/F Pancreas (main duct) Heterotopic gastric corpus
mucosa
– 0.9 PAS, negative: Alcian blue,
chromogranin, serotonin,
somatostatin, gastrin
KRAS exon 1 (p.G12R; c.34G>C)
Kushima (1999) 1 67/F Duodenum Heterotopic gastric corpus
mucosa
– 2.5 MUC5AC (= M1), MUC6
(= M2)
n.k.
Kato (2002) 1 70/M Pancreas (main duct) IPMN – 0.6 PCS, HIK1083, negative:
neuroendocrine markers,
hormones
KRAS exon 1, codon 12
Amaris (2002) 1 73/M Pancreas (branch duct) IPMN – n.k. PAS, negative: Alcian blue n.k.
Vieth (2003) 90 73/F:M = 3:1 Stomach (n =77 ),
duodenal bulb (n = 7),
duodenum (n = 1),
common bile duct
(n = 3), gallbladder
(n = 2)
Gastritis (A-, B-, and C-type)
(20-34%), tubular adenoma
(n = 1), carcinoid tumour





Vieth (2005) 1 46/M Rectum Heterotopic gastric corpus
mucosa
– 3 MUC6, MUC5AC n.k.
Kushima (2005) 1 62/M Esophagus Barrett's mucosa – 3 MUC6, MUC5AC, negative:
MUC2, CD10




Chen (2009) 41 tumours,
36 patients
73/F:M = 25:11 Stomach (19), duodenum
(19), gastroesophageal





n.k. MUC6, MUC5AC, negative:
CDX2, MUC2
n.k.
Wani (2008) 29 n.k. Gallbladder Intestinal metaplasia (34.4%),
squamous morules (24.1%)
– 0.82 MUC6, MUC5AC, M-GGMC-1,
morules: CDX2, beta-catenin
n.k.
Golger (2008) 1 79/F Stomach Helicobacter-negative gastritis – 2 n.k. n.k.

















Table 1 The clinico-pathologic characteristics of previously reported cases of pyloric gland adenoma [2-15] and the case reported here (Continued)
Vieth (2010) 60 70-71/F=M Stomach – Adenocarcinoma
(46.7%)
0.9-1.5 MUC6, MUC5AC (MUC2,





1 49/F Stomach – – n.k. MUC6, MUC5AC, negative:
MUC2
n.k.
Present case 1 62/M Cystic duct IPN, BilIN-3 Adenocarcinoma 2 MUC5AC, MUC6, VEGF, p53,
p21, Ki67, (MUC1, p16),
negative: MUC2, CD10, CDX2
KRAS exon 1 (p.G12V; c.35G>T);
CGH: gains at 1q, 6p11p22, 7p,
15q, 20p, and losses at 6p23pter,
6q14qter, 11q12q13, 18
PGA: Pyloric gland adenoma.
PAS: Periodic Schiff's acid.
PCS: paradoxical concanavalin A.
IPMN: intraductal papillary mucinous neoplasm.
IPN: intraductal papillary neoplasm.
BilIN: biliary intraepithelial neoplasia.
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CGH analyses revealed chromosomal abnormalities com-
mon to invasive gastric adenocarcinoma, including -5q
(50%), -6 (40%), -4q, +17pq and +20 [18,20]. Additional
gains were observed at 1, 3q, 5q, 7, 9q, 11q, 12q, 13q, 15q,
17 and 22q, and losses at 1p, 2q, 4, 9p, 10, 12q 13q, 14q,
16, 18q, 20q, and 21 [20]. Of these aberrations, gains at 7p
and 15q, and losses at 6q, and 18q were also detected in
the present case. Interestingly, losses at 6q and 18q have
been demonstrated in pancreatic IPMN, before [21].
Furthermore, the amplicon at 6p21p22 harbors the
VEGF (VEGF-A) gene at 6p21.1 (MIM ID *192240)
which was shown to be expressed by the pyloric
gland adenoma by immunohistochemical staining,
suggesting VEGF upregulation. VEGF plays a crucial
role in angiogenesis of normal tissues and several
types of tumours [22]. Altogether, the relatively high
number of chromosomal imbalances in the present
case of pyloric gland adenoma of the cystic duct suggests
an instable karyotype and underlines the risk of malignant
transformation.
Conclusions
In conclusion, a pyloric gland adenoma evolving in the
cystic duct is very rare, but may sometimes be over-
looked and therefore should be considered as a differen-
tial diagnosis for obstructive bile duct tumours. An
association with other premalignant bile duct lesions
such as BilIN may be observed. ERCP-guided biopsy
with histopathological examination is necessary to estab-
lish the diagnosis. Due to the high risk of evolving
adenocarcinoma, surgical resection should be performed
whenever possible.
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